Get the Stockscreener App
12.54
16.43%
1.77
Pre-market:
12.96
0.42
+3.35%
Relay Therapeutics Inc stock is traded at $12.54, with a volume of 8.88M.
It is up +16.43% in the last 24 hours and up +28.09% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$10.77
Open:
$10.5
24h Volume:
8.88M
Relative Volume:
3.60
Market Cap:
$2.24B
Revenue:
$15.36M
Net Income/Loss:
$-276.48M
P/E Ratio:
-7.7748
EPS:
-1.6129
Net Cash Flow:
$-235.87M
1W Performance:
+23.91%
1M Performance:
+28.09%
6M Performance:
+140.23%
1Y Performance:
+403.61%
1-Day Range:
$10.48
$13.04
1-Week Range:
$9.275
$13.04
52-Week Range:
$1.775
$13.04
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
12.54 | 2.24B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Relay Therapeutics (RLAY) climbs 16% ahead of cancer treatment update - MSN
Aug Highlights: Can Relay Therapeutics Inc scale operations efficiently2026 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Relay Therapeutics, Inc. Stock? - AAII.com
Relay Therapeutics, Inc. (RLAY) stock price, news, quote and history - Yahoo Finance Singapore
Relay Therapeutics (NASDAQ:RLAY) Reaches New 52-Week HighTime to Buy? - MarketBeat
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Sahm
Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update - insidermonkey.com
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib at Vascular Anomalies Conference - National Today
5 Stocks With Easy 8-20% Gains - Insider Monkey
First zovegalisib results in about 20 vascular anomaly patients due in May - Stock Titan
Relay Therapeutics stock hits 52-week high at $11.52 By Investing.com - Investing.com Canada
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6.4%Here's What Happened - MarketBeat
Relay Therapeutics stock hits 52-week high at $11.52 - Investing.com
Earnings Update: Is Relay Therapeutics Inc likely to announce a buybackEarnings Overview Summary & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Will Relay Therapeutics Inc benefit from government policyQuarterly Profit Report & Community Consensus Picks - baoquankhu1.vn
Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status - simplywall.st
RLAY SEC FilingsRelay Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Relay Therapeutics (RLAY) price target increased by 17.50% to 17.43 - MSN
Vanguard realignment reports 0 Relay Therapeutics shares (RLAY) - Stock Titan
Aug Levels: Will Relay Therapeutics Inc benefit from green energy policies2026 Technical Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - AOL.com
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Relay Ther - GuruFocus
Relay Therapeutics unveils educational resource on mutant selective PI3Kα inhibitor for vascular anomalies - Traders Union
Aug Summary: Will Relay Therapeutics Inc benefit from government policy2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook for RLAY Q1 Earnings - MarketBeat
RLAY: HC Wainwright & Co. Raises Price Target to $19.00, Maintai - GuruFocus
H.C. Wainwright raises Relay Therapeutics price target on trial data By Investing.com - Investing.com Australia
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target on trial data - Investing.com
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Aug Update: What is the earnings history of Relay Therapeutics IncTrade Analysis Report & Target Return Focused Picks - baoquankhu1.vn
Relay Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Relay Therapeutics stock By Investing.com - Investing.com Canada
Profit Review: Can Relay Therapeutics Inc sustain its profitability2026 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Relay Therapeutics Price Target Raised to $17.00 - National Today
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio UpdateNews and Statistics - IndexBox
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo - The Globe and Mail
Portfolio Update: Is Relay Therapeutics Inc a speculative investmentEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
RLAY: Citizens Raises Price Target to $17, Maintains Market Outp - GuruFocus
Relay Therapeutics price target raised to $17 from $15 at Citizens - TipRanks
Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):